- Home
- ASND vs ARCC Comparison
ASND vs ARCC Comparison
Compare ASND & ARCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ASND | ARCC |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 13.6B |
| IPO Year | 2014 | 2004 |
Fundamental Metrics
Financial Performance| Metric | ASND | ARCC |
|---|---|---|
| Price | $225.73 | $17.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 9 |
| Target Price | ★ $278.80 | $22.11 |
| AVG Volume (30 Days) | 713.8K | ★ 8.5M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | ★ 10.63% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.86 |
| Revenue | N/A | N/A |
| Revenue This Year | $98.02 | $6.39 |
| Revenue Next Year | $43.13 | $1.57 |
| P/E Ratio | ★ N/A | $9.72 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $124.06 | $18.08 |
| 52 Week High | $248.60 | $23.42 |
Technical Indicators
Market Signals| Indicator | ASND | ARCC |
|---|---|---|
| Relative Strength Index (RSI) | 46.01 | 29.67 |
| Support Level | $190.49 | N/A |
| Resistance Level | $229.94 | $20.28 |
| Average True Range (ATR) | 9.30 | 0.45 |
| MACD | -1.48 | -0.08 |
| Stochastic Oscillator | 21.99 | 12.56 |
Price Performance
Historical ComparisonAbout ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
About ARCC Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing in first lien senior secured loans (including unitranche loans, which are loans that combine both senior and subordinated debt, generally in a first lien position) and second lien senior secured loans. In addition to senior secured loans, the company also invests in subordinated loans and preferred equity, it also makes common equity investments.